Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...

While Big Pharmas embarked on a frenzy of acquisitions over recent weeks, Roche’s CEO has explained to Fierce Biotech why the ...

Kurma Partners has closed its fourth biotech venture capital fund after raising 215 million euros ($252 million) to support ...

As Sanofi counts down the days before its new leader arrives, the French pharma’s interim CEO acknowledged there had been a ...

Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, ...

Replimune is saying goodbye to a further 161 employees across two Massachusetts sites as the company continues to reel from ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution ...

A pair of Sage Therapeutics veterans has launched a neurology-focused startup armed with $106 million and a clinical-stage ...

McKesson let go of a minority share of its medical/surgical solutions division for $1.25 billion to Apollo Funds as part of ...

Gene therapy biotech Ray Therapeutics has announced the closing of a $125 million series B financing to support the company’s ...

National Cancer Institute Director Anthony Letai, M.D., Ph.D., has attempted to fight back against the “misinformation” ...

Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person syndrome (SPS), ...